amgen weight loss news - Search News

Amgen Stock Dives

Barron's on MSN · 5d

Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.

The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.

Amgen's weight-loss drug fails to impress in study; shares plunge

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

Newsweek on MSN · 3d

Amgen Obesity Drug More Effective Than Competitors

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

4d

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

BioPharma Dive5d

Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

1don MSN

Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

5d

Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

4d

Amgen price target lowered to $330 from $360 at RBC Capital

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results